Oramed Pharmaceuticals (ORMP) Gross Profit (2016 - 2025)

Oramed Pharmaceuticals has reported Gross Profit for 7 years, with the latest figure at $13000.0 in Q1 2025.

• For the quarter ending Q1 2025, Gross Profit changed N/A year-over-year to $13000.0; the trailing twelve-month figure through Dec 2025 stood at $13000.0 (changed N/A YoY), and the FY2025 full-year result was $13000.0, changed N/A from the prior year.
• Gross Profit for Q1 2025 stood at $13000.0, up from -$663000.0 in the prior quarter.
• The five-year high for Gross Profit was $482000.0 in Q1 2023, with the low at -$663000.0 in Q3 2023.
• Historically, Gross Profit has averaged $129000.0 across 3 years, with a median of $219000.0 in 2022.
• The largest YoY upside for Gross Profit was 534.21% in 2023 against a maximum downside of 402.74% in 2023.
• Oramed Pharmaceuticals' Gross Profit stood at $219000.0 in 2022, then tumbled by 402.74% to -$663000.0 in 2023, then surged by 101.96% to $13000.0 in 2025.
• The last three Gross Profit figures came in at $13000.0 (Q1 2025), -$663000.0 (Q3 2023), and $482000.0 (Q2 2023), per Business Quant data.